News und Analysen
Agilent Joins the How2Recycle Program
Agilent Technologies Inc. (NYSE: A) has become a member of How2Recycle®, a standardized labeling system owned by Delaware nonprofit Green Blue Institute, Inc. The program involves a coalition of
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Transgene Reports Business Update And Q3 2022 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on December 5, 2022
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg
Inogen to Present at Upcoming Investor Conferences in November 2022
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following
Puma Biotechnology Reports Third Quarter 2022 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2022. Unless otherwise stated, all comparisons are for
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.
“This has been a year marked by
Acadia Healthcare to Participate in Credit Suisse 31st Annual Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Credit Suisse 31st Annual Healthcare Conference, November 7 - 10, 2022, at Terranea Resort in
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Premier Inc. to Participate in Credit Suisse 31st Annual Healthcare Conference on November 8, 2022
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the
Vistagen to Present at Stifel 2022 Healthcare Conference
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
Simulations Plus (Nasdaq: SLP) today announced its final donation in celebration of 25 years in business. During this 25th anniversary year, which commenced in July 2021, teams of long-tenured
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three months ended September 30, 2022. Amounts, unless specified otherwise, are
EQS-News: Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy through optimized molecular design in preclinical studies
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement